ArriVent BioPharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.5%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$4.37next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Short-term Investments Quarterly326.4MTarget: Sufficient to fund operations into 4Q 2027
FURVENT Phase 3 Trial Topline Data AnnuallyTarget: Positive progression-free survival (PFS) readout in mid-2026
ARR-002 Phase 1 First-in-Human Study Dosing AnnuallyTarget: First patient dosed in 2H 2026
Watch Items
- FURVENT Phase 3 Topline Data ReadoutTrigger: Mid-2026Action: Evaluate clinical efficacy (PFS) and safety profile of firmonertinib monotherapy in first-line EGFR exon 20 insertion mutant NSCLC compared to chemotherapy.
- ARR-002 Phase 1 Trial InitiationTrigger: Second Half of 2026Action: Monitor the initiation of clinical development and first patient dosing for the novel tetravalent MUC16/NaPi2b targeting ADC.
- ALPACCA Phase 3 Trial EnrollmentTrigger: Ongoing through 2026Action: Track global patient recruitment progress for firmonertinib in first-line EGFR PACC mutant NSCLC.
Research as of 19 Jun 2026